New pill could help control rare hormone disorder, reduce steroid dependence
NCT ID NCT07144163
Summary
This study is testing whether a daily pill called atumelnant can better control hormone levels in adults with classic congenital adrenal hyperplasia (CAH), a rare genetic condition. About 150 participants will receive either atumelnant or a placebo pill for comparison. The main goals are to see if the medicine safely reduces abnormal hormone levels and allows people to take lower doses of their current steroid medications.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CONGENITAL ADRENAL HYPERPLASIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Crinetics Study Site
RECRUITINGAnn Arbor, Michigan, 48109, United States
-
Crinetics Study Site
RECRUITINGBuenos Aires, Buenos Aires F.D., C1012AAR, Argentina
-
Crinetics Study Site
RECRUITINGHerston, Queensland, 4029, Australia
-
Crinetics Study Site
RECRUITINGWoolloongabba, Queensland, 4102, Australia
-
Crinetics Study Site
RECRUITINGAdelaide, South Australia, 5000, Australia
-
Crinetics Study Site
RECRUITINGParkville, Victoria, 3050, Australia
-
Crinetics Study Site
RECRUITINGNedlands, Western Australia, 6009, Australia
-
Crinetics Study Site
RECRUITINGSão Paulo, São Paulo, 05403-000, Brazil
Conditions
Explore the condition pages connected to this study.